Key result
Comparative outcomes between Allegra and Evolut self-expanding valves remain unclarified in this report.
Why the study?
Direct comparisons between the Allegra and other contemporary self-expanding transcatheter heart valve platforms remain limited, especially beyond three years of follow-up.
Does the Allegra self-expanding valve improve procedural, 30-day, and five-year outcomes compared to the Evolut valve in patients undergoing TAVR?
Observational
Does the Allegra self-expanding valve improve procedural, 30-day, and five-year outcomes compared to the Evolut valve in patients undergoing TAVR?
Compares procedural, 30-day, and five-year outcomes of Allegra versus Evolut valves in transcatheter aortic valve replacement, highlighting long-term bioprosthetic performance.
The Evolut platform (Medtronic, Minneapolis, Minnesota) is the most extensively studied self-expanding transcatheter heart valve. Evidence for the more recently introduced supra-annular Allegra valve (Biosensors International, Singapore) derives largely from single-arm registries with follow-up of three years or less,1,2 and direct comparisons between the Allegra and other contemporary self-expanding platforms remain limited.3 Therefore, we aimed to compare procedural, 30-day and up to five-year outcomes of the two platforms.
No takes yet. Share an insight, caveat, or question.
Alexiou et al. (2026) conducted an observational in Transcatheter Aortic Valve Replacement. Allegra self-expanding valve vs. Evolut self-expanding valve was evaluated on Procedural, 30-day and up to five-year outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: